株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

骨髄異形成症候群治療薬の世界市場:2018年〜2022年

Global Myelodysplastic Syndrome Therapeutics Market 2018-2022

発行 TechNavio (Infiniti Research Ltd.) 商品コード 665969
出版日 ページ情報 英文 119 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.53円で換算しております。
Back to Top
骨髄異形成症候群治療薬の世界市場:2018年〜2022年 Global Myelodysplastic Syndrome Therapeutics Market 2018-2022
出版日: 2018年07月10日 ページ情報: 英文 119 Pages
概要

骨髄異形成症候群治療薬について

骨髄異形成症候群(MDS)は、無効造血、異常な血液および骨髄細胞形態による血球減少症、クローン進化およびAMLへの進行のリスクを特徴とする、一群のクローン性骨髄性腫瘍です。

Technavioのアナリストは、世界の骨髄異形成症候群治療薬市場は、2018年から2022年の間に2.54%のCAGRで成長すると予測しています。

当レポートでは、世界の骨髄異形成症候群治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 調査方法

第4章 市場状況

  • 市場のエコシステム
  • 市場特性
  • 市場セグメンテーション分析

第5章 パイプライン分析

  • MDSパイプライン

第6章 市場規模

  • 市場の定義
  • 市場規模(2017年)
  • 市場規模および予測(2017-2022年)

第7章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市場状況

第8章 市場セグメンテーション:投与経路別

  • セグメンテーション:投与経路別(2017-2022年)
  • 投与経路別比較
  • 経口薬
  • 非経口薬
  • 市場機会:投与経路別

第9章 市場セグメンテーション:MDSのサブタイプ別

  • セグメンテーション:MDSのサブタイプ別

第10章 顧客情勢

第11章 地域情勢

  • 地域別セグメンテーション(2017-2022年)
  • 地域比較
  • 南北アメリカ
  • 欧州・中東・アフリカ地域
  • アジア太平洋地域
  • 市場機会

第12章 意思決定の枠組み

第13章 成長要因と課題

  • 市場の成長要因
  • 市場の課題

第14章 市場動向

  • 高い病気管理コスト
  • 高齢者の高発生率

第15章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第16章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • Celgene
  • 大塚製薬
  • Novartis

第17章 付録

  • 略語のリスト
図表
  • Exhibit 01: Global oncology market
  • Exhibit 02: Parent market: The global oncology market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Drugs approved by US FDA for MDS
  • Exhibit 06: Drugs approved by European Medicines Agency (EMA) for MDS
  • Exhibit 07: MDS pipeline phase II development stage agents
  • Exhibit 08: MDS pipeline phase III development stage agents
  • Exhibit 09: Treatment Algorithm in MDS
  • Exhibit 10: Market definition - Inclusions and exclusions checklist
  • Exhibit 11: Market size 2017
  • Exhibit 12: Validation techniques employed for market sizing 2017
  • Exhibit 13: Global MDS therapeutics market - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 14: Global MDS therapeutics market - Year-over-year growth 2018-2022 (%)
  • Exhibit 15: Five forces analysis 2017
  • Exhibit 16: Five forces analysis 2022
  • Exhibit 17: Bargaining power of buyers
  • Exhibit 18: Bargaining power of suppliers
  • Exhibit 19: Threat of new entrants
  • Exhibit 20: Threat of substitutes
  • Exhibit 21: Threat of rivalry
  • Exhibit 22: Market condition - Five forces 2017
  • Exhibit 23: Global MDS therapeutics market by ROA - Market share 2017-2022 (%)
  • Exhibit 24: Comparison by ROA
  • Exhibit 25: Oral drugs - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 26: Oral drugs - Year-over-year growth 2018-2022 (%)
  • Exhibit 27: Parenteral drugs - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 28: Parenteral drugs - Year-over-year growth 2018-2022 (%)
  • Exhibit 29: Market opportunity by route of administration
  • Exhibit 30: Customer landscape
  • Exhibit 31: Global MDS therapeutics market by geography - Market share 2017-2022 (%)
  • Exhibit 32: Regional comparison
  • Exhibit 33: Americas - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 34: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 35: Top 3 countries in Americas
  • Exhibit 36: EMEA - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 37: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 38: Top 3 countries in EMEA
  • Exhibit 39: APAC - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 40: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 41: Top 3 countries in APAC
  • Exhibit 42: Market opportunity
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Market positioning of vendors
  • Exhibit 47: Vendor classification
  • Exhibit 48: Celgene overview
  • Exhibit 49: Celgene- Business segments
  • Exhibit 50: Celgene - Organizational developments
  • Exhibit 51: Celgene - Geographic focus
  • Exhibit 52: Celgene - Segment focus
  • Exhibit 53: Celgene - Key Offerings
  • Exhibit 54: Otsuka overview
  • Exhibit 55: Otsuka - Business segments
  • Exhibit 56: Otsuka - Organizational developments
  • Exhibit 57: Otsuka - Geographic focus
  • Exhibit 58: Otsuka - Segment focus
  • Exhibit 59: Otsuka- Key offerings
  • Exhibit 60: Novartis overview
  • Exhibit 61: Novartis - Business segments
  • Exhibit 62: Novartis - Organizational developments
  • Exhibit 63: Novartis - Geographic focus
  • Exhibit 64: Novartis - Segment focus
  • Exhibit 65: Novartis - Key offerings
目次
Product Code: IRTNTR23344

About Myelodysplastic Syndrome Therapeutics

Myelodysplastic syndrome (MDS) includes a group of clonal myeloid neoplasms characterized by cytopenia due to ineffective hematopoiesis, abnormal blood and marrow cell morphology, and a risk of clonal evolution and progression to AML.

Technavio's analysts forecast the global myelodysplastic syndrome therapeutics market to grow at a CAGR of 2.54% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global myelodysplastic syndrome therapeutics market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of patented and generic drugs used to treat MDS.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Myelodysplastic Syndrome Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Celgene
  • Otsuka
  • Novartis

Market driver

  • Improved prognostic classification of MDS through advanced technologies
  • For a full, detailed list, view our report

Market challenge

  • Inadequacies in treatment landscape of MDS
  • For a full, detailed list, view our report

Market trend

  • High incidence in older adult population
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

  • MDS Pipeline

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION

  • Segmentation by ROA
  • Comparison by ROA
  • Oral drugs - Market size and forecast 2017-2022
  • Parenteral Drugs - Market size and forecast 2017-2022
  • Market opportunity by route of administration

PART 09: MARKET SEGMENTATION BY SUB-TYPE OF MDS

  • Segmentation by sub-type of MDS

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 14: MARKET TRENDS

  • High cost of disease-management
  • High incidence in older adult population

PART 15: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Market positioning of vendors
  • Celgene
  • Otsuka
  • Novartis

PART 17: APPENDIX

  • List of abbreviations
Back to Top